

CANN GROUP LIMITED

ASX ANNOUNCEMENT

23 July 2021

INVESTOR WEBINAR

23 July 2021 – Cann Group Limited (ASX: CAN) (**Cann or the Company**) is pleased to announce it will hold an investor webinar on **Monday 26 July 2021 at 11.00am AEST** with CEO Peter Crock and COO Shane Duncan to discuss the outcome of the Company's capital raise.

Investors are invited to send questions prior to the webinar to matt@nwrcommunications.com.au

Register for the investor webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_SBXwt5MOSqqtOyzRX74wZw

After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be made available shortly after the conclusion of the webinar at the same link.

To join the webinar via telephone, please use one of the following numbers and enter the **Webinar ID: 892 3777 9109**

For higher quality, dial a number based on your current location:

+61 3 7018 2005 or
+61 7 3185 3730 or
+61 8 6119 3900 or
+61 8 7150 1149 or
+61 2 8015 6011

International numbers available: <https://us02web.zoom.us/j/km17ZPrV9>

Authorised for release by the Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock CEO Cann Group Limited +61 3 9095 7088 contact@cann grouplimited.com	Clive Fanning Head of Investor Relations Cann Group Limited +61 3 9095 7088 clive.fanning@cann grouplimited.com
---	--

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.cann grouplimited.com | www.satipharm.com